MedTrace Logo

Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer

NCT01195298 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2010-09-06

No results posted yet for this study

Summary

This is an open-label, single-arm, multicenter study of capecitabine and bevacizumab administered as first-line treatment of previously untreated elderly patients, older than 70 years, with metastatic or locally recurrent breast cancer.

Conditions

Interventions

DRUG

Capecitabine and Bevacizumab

Drugs will be administered in 3-week cycles as follows: * Bevacizumab 15mg/kg via i.v. infusion on day 1 * Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14.

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • South Eastern European Research Oncology Group

    lead OTHER

Principal Investigators

  • Eduard Vrdoljak, PhD MD · Clinical Hospital Split, Center of oncology, Croatia

  • Damir Vrbanec, PhD MD · Clinical Hospital Zagreb, Croatia

  • Katarina Petrakova, MD · Masaryk Memorial Cancer Institue, Brno, Czech Republic

  • Gyorgy Bodoky, PhD MD · FOVAROSI SZENT LASZLO KORHAZ-RENDELOINTEZET, ONKOLOGIAI OSZTALY, Budapest, Hungary

  • Tamas Pinter, MD · Petz, Aladar Korhaz, Onkoradiologiai Osztaly, Gyor, Hungary

  • Vladimir Todorović, MD · Oncology clinic, Clinical Center of Montenegro

  • Marek Wojtukiewicz, PhD MD · Department of Oncology Medical University, Bialystok, Poland

  • Tadeusz Pienkowski, PhD MD · Cancer Centre and Institute of Oncology Warsaw

  • Daniela Grecea, MD · "Prof Dr. I Chiricuta" Cluj Napoca Oncology Institute - Breast Cancer Center, Cluj Napoca, Romania

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-08-31

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01195298 on ClinicalTrials.gov